BG103964A - Заместени пиразоли като инхибитори на р38 киназата - Google Patents

Заместени пиразоли като инхибитори на р38 киназата

Info

Publication number
BG103964A
BG103964A BG103964A BG10396499A BG103964A BG 103964 A BG103964 A BG 103964A BG 103964 A BG103964 A BG 103964A BG 10396499 A BG10396499 A BG 10396499A BG 103964 A BG103964 A BG 103964A
Authority
BG
Bulgaria
Prior art keywords
pyrazols
substituted
kinase inhibitors
pyrazol
kinase
Prior art date
Application number
BG103964A
Other languages
English (en)
Other versions
BG64313B1 (bg
Inventor
Ashok Anantanarayan
Michael Clare
Paul Collins
Joyce Crich
Rajesh Devraj
Daniel Flynn
Lifeng Geng
Gunnar Hanson
Francis Koszyk
Shuyuan Liao
Richard Partis
Shashidhar RAO
Shaun Selness
Michael South
Ish Khanna
Yi Yu
Original Assignee
G.D.Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D.Searle & Co filed Critical G.D.Searle & Co
Publication of BG103964A publication Critical patent/BG103964A/bg
Publication of BG64313B1 publication Critical patent/BG64313B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретението се отнася до нов клас производни напиразола, до състави на основата на пиразол и до методи за лечение на нарушения, предизвикани от р38 киназа. Съединенията имат формула І@@в която R1,R2, R3 и R4 имат значения, посочени в описанието.
BG103964A 1997-05-22 1999-12-08 ЗАМЕСТЕНИ ПИРАЗОЛИ КАТО ИНХИБИТОРИ НА р38 КИНАЗАТА BG64313B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
BG103964A true BG103964A (bg) 2000-08-31
BG64313B1 BG64313B1 (bg) 2004-09-30

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103964A BG64313B1 (bg) 1997-05-22 1999-12-08 ЗАМЕСТЕНИ ПИРАЗОЛИ КАТО ИНХИБИТОРИ НА р38 КИНАЗАТА

Country Status (24)

Country Link
EP (1) EP1000055A1 (bg)
JP (1) JP2002508754A (bg)
KR (1) KR20010012854A (bg)
CN (1) CN1264377A (bg)
AP (1) AP1246A (bg)
AU (1) AU754830C (bg)
BG (1) BG64313B1 (bg)
BR (1) BR9809147A (bg)
CA (1) CA2291115A1 (bg)
EA (1) EA003925B1 (bg)
EE (1) EE9900527A (bg)
GE (1) GEP20033053B (bg)
HU (1) HUP0001880A3 (bg)
ID (1) ID22982A (bg)
IL (1) IL132991A (bg)
IS (1) IS5257A (bg)
NO (1) NO995695L (bg)
NZ (1) NZ501112A (bg)
OA (1) OA12981A (bg)
PL (1) PL337020A1 (bg)
SK (1) SK157899A3 (bg)
TR (1) TR200000235T2 (bg)
WO (1) WO1998052940A1 (bg)
ZA (1) ZA984358B (bg)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (bg) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002526388A (ja) 1998-10-07 2002-08-20 スミスクライン・ビーチャム・コーポレイション 発作を管理するための新規な処置
DE69903976T2 (de) 1998-12-16 2003-07-24 Aventis Pharma Ltd Heteroaryl-zyklische acetale
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
JP4632544B2 (ja) * 1998-12-25 2011-02-16 あすか製薬株式会社 アミノピラゾール誘導体
WO2000057877A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
ATE296820T1 (de) 1999-06-03 2005-06-15 Teikoku Hormone Mfg Co Ltd Substituierte pyrazol-derivate
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
WO2001030154A2 (de) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Pyrazole enthaltende agrochemische zusammensetzungen und ihre verwendung als fungizide flanzenschutzmittel
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE60015599T2 (de) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
EP1309592B9 (en) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
WO2002088107A1 (en) 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
EP1429773A1 (en) 2001-09-25 2004-06-23 Pharmacia Corporation Process for making substituted pyrazoles
WO2003104223A1 (en) * 2002-06-05 2003-12-18 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
JPWO2004069824A1 (ja) 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ES2375633T3 (es) 2004-12-28 2012-03-02 Aska Pharmaceutical Co., Ltd. Derivado de pirimidinilisoxazol.
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
KR101412943B1 (ko) 2006-06-28 2014-06-26 아스카 세이야쿠 가부시키가이샤 피리딜이소옥사졸 유도체
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
JP4588791B2 (ja) 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EA201070143A1 (ru) * 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
AR069545A1 (es) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
AR071719A1 (es) 2008-05-13 2010-07-07 Boehringer Ingelheim Int Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
EA019722B1 (ru) 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
US8609690B2 (en) * 2008-08-25 2013-12-17 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
KR20110070885A (ko) * 2008-10-23 2011-06-24 론자 리미티드 치환된 피라졸의 합성 방법
RU2528406C2 (ru) * 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
BR112012008075A2 (pt) * 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
AU2011209234B2 (en) 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2654750B1 (en) * 2010-12-20 2017-03-08 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
EP2744783A1 (en) 2011-08-17 2014-06-25 Boehringer Ingelheim International GmbH Indenopyridine derivatives
BR112014008222A2 (pt) 2011-10-06 2017-04-25 Bayer Intelectual Property Gmbh heterociclilpiri (mi) dinilpirazol
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
BR112016012482B1 (pt) * 2013-12-12 2020-07-21 Sumitomo Chemical Company, Limited composto aromático, seu uso, agente e método de controle de peste
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
EP3303284B1 (en) * 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN109748873B (zh) * 2017-11-08 2021-02-02 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
OA12981A (en) 2006-10-13
JP2002508754A (ja) 2002-03-19
NO995695D0 (no) 1999-11-19
NO995695L (no) 2000-01-21
EP1000055A1 (en) 2000-05-17
CA2291115A1 (en) 1998-11-26
EA199900953A1 (ru) 2000-10-30
BR9809147A (pt) 2000-08-01
AU754830B2 (en) 2002-11-28
AP9901715A0 (en) 1999-12-31
IS5257A (is) 1999-11-19
BG64313B1 (bg) 2004-09-30
KR20010012854A (ko) 2001-02-26
ID22982A (id) 1999-12-23
GEP20033053B (en) 2003-08-25
EA003925B1 (ru) 2003-10-30
EE9900527A (et) 2000-06-15
AU754830C (en) 2004-02-12
CN1264377A (zh) 2000-08-23
SK157899A3 (en) 2000-08-14
IL132991A (en) 2005-11-20
AP1246A (en) 2004-02-07
NZ501112A (en) 2002-10-25
IL132991A0 (en) 2001-03-19
ZA984358B (en) 1999-05-24
TR200000235T2 (tr) 2000-05-22
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
AU7588398A (en) 1998-12-11
HUP0001880A2 (en) 2001-03-28
HUP0001880A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
BG103964A (bg) Заместени пиразоли като инхибитори на р38 киназата
BG103195A (bg) Индазолови производни, фармацевтични състави и използването им
AP2001002172A0 (en) Substituted pyrazoles as p38 kinase inhibitors
BG103485A (bg) Кетобензамиди като инхибитори на калпаина
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
AP2002002637A0 (en) Novel piperazine
BG103413A (bg) Производни на сулфиновата киселина, тяхното получаване и използване
BG106585A (bg) Киназни инхибитори като лекарствени средства
PL338452A1 (en) Novel substituted 6-phenylphenatridines
AP2001002088A0 (en) 4,4-Biarylpiperidine derivatives with opiod receptor activity.
BG104138A (bg) 2-аминопиридини, съдържащи заместители с кондензирани пръстени, като nоs инхибитори
MXPA02011370A (es) Iminoazinas substituidas.
BG103310A (bg) Бензонафтиридини като бронхиални лечебни средства
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
BG105710A (bg) 5-нт1 антагонисти за антидепресантно лечение
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
MX9702203A (es) Derivados de pirazolil-pirazol substituidos, procedimientos para su preparacion y su uso como agentes con accion herbicida.
MXPA02001406A (es) Heterociclilos-2h-cromenos substituidos.
BG105247A (bg) N-заместени азабициклохептанови производни, тяхното получаване и използване
ZA983231B (en) Substituted benzyloxyimino compounds.
BG105618A (bg) -амидо и -сулфонамидни производни на карбоксилни киселини, метод за тяхното получаване и приложението им като ендотелин-рецепторни антагонисти
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister
BG105329A (bg) N-заместени азабициклохептанови производни, тяхното получаване и използване